PubRank

Neng-Yang Shih

Author PubWeight™ 25.65‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. Acc Chem Res 2008 1.14
2 Asymmetric synthesis of 4,4-disubstituted-2-imidazoli-dinones: potent NK1 antagonists. Org Lett 2003 0.86
3 Discovery of potent sulfonamide P4-capped ketoamide second generation inhibitors of hepatitis C virus NS3 serine protease with favorable pharmacokinetic profiles in preclinical species. Bioorg Med Chem 2010 0.86
4 Cyclic urea derivatives as potent NK1 selective antagonists. Bioorg Med Chem Lett 2005 0.85
5 Cyclic urea derivatives as potent NK1 selective antagonists. Part II: Effects of fluoro and benzylic methyl substitutions. Bioorg Med Chem Lett 2005 0.84
6 A novel class of highly potent irreversible hepatitis C virus NS5B polymerase inhibitors. J Med Chem 2012 0.82
7 The synthesis of substituted bipiperidine amide compounds as CCR3 antagonists. Bioorg Med Chem Lett 2005 0.82
8 III. Identification of novel CXCR3 chemokine receptor antagonists with a pyrazinyl-piperazinyl-piperidine scaffold. Bioorg Med Chem Lett 2011 0.82
9 Discovery and structure-activity relationship of P1-P3 ketoamide derived macrocyclic inhibitors of hepatitis C virus NS3 protease. J Med Chem 2009 0.81
10 Cyclobutane derivatives as potent NK1 selective antagonists. Bioorg Med Chem Lett 2006 0.81
11 Application of ring-closing metathesis for the synthesis of macrocyclic peptidomimetics as inhibitors of HCV NS3 protease. Org Lett 2007 0.80
12 Structure-activity relationship (SAR) development and discovery of potent indole-based inhibitors of the hepatitis C virus (HCV) NS5B polymerase. J Med Chem 2012 0.80
13 Second-generation highly potent and selective inhibitors of the hepatitis C virus NS3 serine protease. J Med Chem 2009 0.80
14 The discovery of novel tartrate-based TNF-alpha converting enzyme (TACE) inhibitors. Bioorg Med Chem Lett 2009 0.80
15 Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687). J Pharmacol Exp Ther 2003 0.79
16 Discovery of a series of potent, orally active α,α-disubstituted piperidine NK(1) antagonists. Bioorg Med Chem Lett 2010 0.78
17 Identification of a dual histamine H1/H3 receptor ligand based on the H1 antagonist chlorpheniramine. Bioorg Med Chem Lett 2003 0.78
18 II. SAR studies of pyridyl-piperazinyl-piperidine derivatives as CXCR3 chemokine antagonists. Bioorg Med Chem Lett 2010 0.78
19 Triaryl bis-sulfones as cannabinoid-2 receptor ligands: SAR studies. Bioorg Med Chem Lett 2005 0.78
20 Biaryl substituted hydantoin compounds as TACE inhibitors. Bioorg Med Chem Lett 2010 0.77
21 5-Benzothiazole substituted pyrimidine derivatives as HCV replication (replicase) inhibitors. Bioorg Med Chem Lett 2012 0.77
22 Reduction of CYP450 inhibition in the 4-[(1H-imidazol-4-yl)methyl]piperidine series of histamine H3 receptor antagonists. Bioorg Med Chem Lett 2005 0.77
23 I. Novel HCV NS5B polymerase inhibitors: discovery of indole 2-carboxylic acids with C3-heterocycles. Bioorg Med Chem Lett 2011 0.77
24 2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors. Bioorg Med Chem Lett 2011 0.77
25 Discovery of a highly potent series of oxazole-based phosphodiesterase 4 inhibitors. Bioorg Med Chem Lett 2007 0.77
26 Preparation of oxime dual NK(1)/NK(2) antagonists with reduced NK(3) affinity. Bioorg Med Chem Lett 2002 0.76
27 Optimization of triaryl bis-sulfones as cannabinoid-2 receptor ligands. Bioorg Med Chem Lett 2007 0.76
28 Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitors. Bioorg Med Chem Lett 2009 0.76
29 Discovery of an irreversible HCV NS5B polymerase inhibitor. Bioorg Med Chem Lett 2013 0.76
30 SCH 206272: a potent, orally active tachykinin NK(1), NK(2), and NK(3) receptor antagonist. Eur J Pharmacol 2002 0.76
31 The synthesis of substituted bipiperidine amide compounds as CCR3 ligands: antagonists versus agonists. Bioorg Med Chem Lett 2005 0.75
32 Discovery of oxazole-based PDE4 inhibitors with picomolar potency. Bioorg Med Chem Lett 2012 0.75
33 Manipulation of N,O-nucleophilicity: efficient formation of 4-N-substituted 2,4-dihydro-3H-1,2,4-triazolin-3-ones. Org Lett 2004 0.75
34 Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors. Bioorg Med Chem Lett 2010 0.75
35 8-Methoxyquinolines as PDE4 inhibitors. Bioorg Med Chem Lett 2002 0.75
36 Discovery and SAR of hydantoin TACE inhibitors. Bioorg Med Chem Lett 2010 0.75
37 Discovery of a novel, potent and orally active series of gamma-lactams as selective NK1 antagonists. Bioorg Med Chem Lett 2008 0.75
38 Benzimidazole-substituted (3-phenoxypropyl)amines as histamine H3 receptor ligands. Bioorg Med Chem Lett 2008 0.75
39 Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonists. Bioorg Med Chem Lett 2013 0.75
40 Pyridofuran substituted pyrimidine derivatives as HCV replication (replicase) inhibitors. Bioorg Med Chem Lett 2012 0.75
41 Development and potential utility of dual and triple NK receptor antagonists. Curr Top Med Chem 2003 0.75
42 Discovery of novel spirocyclopropyl hydroxamate and carboxylate compounds as TACE inhibitors. Bioorg Med Chem Lett 2008 0.75
43 II. Novel HCV NS5B polymerase inhibitors: discovery of indole C2 acyl sulfonamides. Bioorg Med Chem Lett 2011 0.75
44 Potent aza-peptide derived inhibitors of HCV NS3 protease. Bioorg Med Chem Lett 2009 0.75
45 Discovery of novel tricyclic indole derived inhibitors of HCV NS5B RNA dependent RNA polymerase. Bioorg Med Chem 2013 0.75
46 Synthesis and profile of SCH351591, a novel PDE4 inhibitor. Bioorg Med Chem Lett 2002 0.75
47 Synthesis and NK(1)/NK(2) binding activities of a series of diacyl-substituted 2-arylpiperazines. Bioorg Med Chem Lett 2002 0.75
48 Structure and activity relationships of tartrate-based TACE inhibitors. Bioorg Med Chem Lett 2010 0.75
49 Novel TNF-α converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases. Bioorg Med Chem Lett 2010 0.75
50 Novel histamine H3 receptor antagonists based on the 4-[(1H-imidazol-4-yl)methyl]piperidine scaffold. Bioorg Med Chem Lett 2005 0.75
51 Stereoselective synthesis of beta-substituted beta-amino sulfones and sulfonamides via addition of sulfonyl anions to chiral N-sulfinyl imines. Org Lett 2006 0.75
52 Novel substituted pyrimidines as HCV replication (replicase) inhibitors. Bioorg Med Chem Lett 2011 0.75
53 Synthesis and SAR of pyridothiazole substituted pyrimidine derived HCV replication inhibitors. Bioorg Med Chem Lett 2012 0.75